Intranasal immunization of young mice with a multigene HIV-1 vaccine in combination with the N3 adjuvant induces mucosal and systemic immune responses

被引:17
作者
Brave, Andreas [1 ,2 ]
Hallengard, David [1 ,2 ]
Schroder, Ulf [3 ]
Blomberg, Pontus [4 ]
Wahren, Britta [1 ,2 ]
Hinkula, Jorma [5 ]
机构
[1] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden
[2] Swedish Inst Infect Dis Control, Stockholm, Sweden
[3] Karolinska Inst, Eurocine Vaccines AB, Stockholm, Sweden
[4] Karolinska Univ Hosp, Huddinge, Sweden
[5] Linkoping Univ, Dept Mol & Clin Med, Div Mol Virol, S-58183 Linkoping, Sweden
关键词
AIDS; IgA; IgG; T cells; plasmid;
D O I
10.1016/j.vaccine.2008.03.066
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
One of the major challenges for the development of an HIV vaccine is to induce potent virus-specific immune responses at the mucosal surfaces where transmission of virus occurs. Intranasal delivery of classical vaccines has been shown to induce good mucosal antibody responses, but so far for genetic vaccines the success has been limited. This study shows that young individuals are sensitive to nasal immunization with a genetic vaccine delivered in a formulation of a lipid adjuvant, the Eurocine N3. Intranasal delivery of a multiclade/multigene HIV-1 genetic vaccine gave rise to vaginal and rectal IgA responses as well as systemic humoral and cellular responses. As electroporation might become the preferred means of delivering genetic vaccines for systemic HIV immunity, nasal delivery by droplet formulation in a lipid adjuvant might become a means of priming or boosting the mucosal immunity. (C) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:5075 / 5078
页数:4
相关论文
共 18 条
[1]   Immunisation schedules for non-replicating nasal vaccines can be made simple by allowing time for development of immunological memory [J].
Bakke, H ;
Setek, TN ;
Huynh, PN ;
Haugen, IL ;
Hoiby, EA ;
Holst, J ;
Aaberge, IS ;
Haneberg, B .
VACCINE, 2004, 22 (17-18) :2278-2284
[2]   Multigene/multisubtype HIV-1 vaccine induces potent cellular and humoral immune responses by needle-free intradermal delivery [J].
Bråve, A ;
Ljungberg, K ;
Boberg, A ;
Rollman, E ;
Isaguliants, M ;
Lundgren, B ;
Blomberg, P ;
Hinkula, J ;
Wahren, B .
MOLECULAR THERAPY, 2005, 12 (06) :1197-1205
[3]   Reduced cellular immune responses following immunization with a multi-gene HIV-1 vaccine [J].
Brave, Andreas ;
Ljungberg, Karl ;
Boberg, Andreas ;
Rollman, Erik ;
Engstrom, Gunnel ;
Hinkula, Jorma ;
Wahren, Britta .
VACCINE, 2006, 24 (21) :4524-4526
[4]   Intranasal administration of HIV-DNA vaccine formulated with a polymer, carboxymethylcellulose, augments mucosal antibody production and cell-mediated immune response [J].
Hamajima, K ;
Sasaki, S ;
Fukushima, J ;
Kaneko, T ;
Xin, KQ ;
Kudoh, I ;
Okuda, K .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1998, 88 (02) :205-210
[5]   A novel DNA adjuvant, N3, enhances mucosal and systemic immune responses induced by HIV-1 DNA and peptide immunizations [J].
Hinkula, Jorma ;
Devito, Claudia ;
Zuber, Bartek ;
Benthin, Reinhold ;
Ferreira, Denise ;
Wahren, Britta ;
Schroder, Ulf .
VACCINE, 2006, 24 (21) :4494-4497
[6]   DNA-encoding enzymatically active HIV-1 reverse transcriptase, but not the inactive mutant, confers resistance to experimental HIV-1 challenge [J].
Isaguliants, MG ;
Petrakova, N ;
Zuber, B ;
Pokrovskaya, K ;
Gizatullin, R ;
Kostyuk, DA ;
Kjerrström, A ;
Winberg, G ;
Kochetkov, SN ;
Hinkula, J ;
Wahren, B .
INTERVIROLOGY, 2000, 43 (4-6) :288-293
[7]   Interactions of single and combined human immunodeficiency virus type 1 (HIV-1) DNA vaccines [J].
Kjerrström, A ;
Hinkula, J ;
Engström, G ;
Ovod, V ;
Krohn, K ;
Benthin, R ;
Wahren, B .
VIROLOGY, 2001, 284 (01) :46-61
[8]   Interaction of antigens and antibodies at mucosal surfaces [J].
Lamm, ME .
ANNUAL REVIEW OF MICROBIOLOGY, 1997, 51 :311-340
[9]   Enhanced immune responses after DNA vaccination with combined envelope genes from different HIV-1 subtypes [J].
Ljungberg, K ;
Rollman, E ;
Eriksson, L ;
Hinkula, J ;
Wahren, B .
VIROLOGY, 2002, 302 (01) :44-57
[10]   The need for IgG2c specific antiserum when isotyping antibodies from C57BL/6 and NOD mice [J].
Martin, RM ;
Brady, JL ;
Lew, AM .
JOURNAL OF IMMUNOLOGICAL METHODS, 1998, 212 (02) :187-192